



Contact: Dr. John Yu, Chairman of the Board
ImmunoCellular Therapeutics, Ltd.
(310) 423-0845

ImmunoCellular Therapeutics to Hold Investor Conference Call

LOS ANGELES, CA – November 26, 2007 – ImmunoCellular Therapeutics, Ltd. (OTC: IMUC.OB) ("IMUC") announced today that it will be holding an investor telephone conference call to discuss its new agreement to acquire a monoclonal antibody technology that was reported in a press release by IMUC earlier today and to update investors on IMUC's other activities. The conference call will be held at 7:30 a.m. PST on Thursday, November 29, 2007. The call-in number for U.S. and Canadian investors will be 888-677-5725, and for other international investors, the call-in number will be 210-839-8725. The passcode for both numbers will be IMUC.

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles, California based development stage company that will seek to develop cellular therapies for the treatment of brain and other cancers as well as neurodegenerative disorders. IMUC's initial focus will be on a dendritic cell-based vaccine for treating brain tumors, with a Phase I trial for its lead vaccine product candidate having commenced in May 2007.

###